Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14344644 | 0.82 | SLC10A1 (0.46) | SLC10A1PTPN1USP2LMNAHIF1A | |
| SCHEMBL5444226 | 0.80 | CA9 (0.54) | SLC10A1CA9CA1CA2PTPN1 | |
| SCHEMBL5448193 | 0.80 | SLC10A1 (0.40) | SLC10A1PTPN1USP2LMNAHIF1A | |
| SCHEMBL16669528 | 0.77 | USP7 (0.45) | CA9CA1CA2PTPN1USP2 | |
| SCHEMBL16671510 | 0.77 | USP7 (0.45) | CA9CA1CA2PTPN1USP2 | |
| SCHEMBL16669216 | 0.74 | NT5E (0.47) | PTPN1USP2LMNAHIF1ANT5E | |
| SCHEMBL14374214 | 0.73 | CA9 (0.69) | SLC10A1CA9CA1CA2PTPN1 | |
| SCHEMBL13098060 | 0.73 | CA9 (0.69) | SLC10A1CA9CA1CA2PTPN1 | |
| SCHEMBL14374360 | 0.72 | PTPN1 (0.56) | SLC10A1CA9CA1CA2PTPN1 | |
| SCHEMBL13098042 | 0.72 | PTPN1 (0.68) | SLC10A1CA9CA1CA2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | ADVANCED LIFE SCIENCES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | BET1, PGGT1B, BRCA1 | SLC10A1 2120/4885CA9 779/4885CA1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.